Hepatitis Monthly

Published by: Kowsar

Probiotic as a Novel Treatment Strategy Against Liver Disease

Abbas Ali Imani Fooladi 1 , * , Hamideh Mahmoodzadeh Hosseini 2 , Mohammad Reza Nourani 3 , Soghra Khani 4 and Seyed Moayed Alavian 5
Authors Information
1 Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2 School of Pharmacy, Student's Research Committee, Tabriz University of Medical Sciences, Tabriz, IR Iran
3 Tissue Engineering Division, Chemical Injury Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
4 Department of Biochemistry, Pasteur Institute of Iran, Tehran, IR Iran
5 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: February 01, 2012, 13 (2); e7521
  • Published Online: February 25, 2013
  • Article Type: Review Article
  • Received: July 30, 2012
  • Revised: September 19, 2012
  • Accepted: September 25, 2012
  • DOI: 10.5812/hepatmon.7521

To Cite: Imani Fooladi A A, Hosseini H M, Nourani M R, Khani S, Alavian S M. et al. Probiotic as a Novel Treatment Strategy Against Liver Disease, Hepat Mon. 2012 ;13(2):e7521. doi: 10.5812/hepatmon.7521.

Abstract
Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Conclusions
Acknowledgements
Footnotes
References
  • 1. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol. 2003; 38(5): 681-7[PubMed]
  • 2. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. PLoS Biol. 2007; 5(7)[DOI][PubMed]
  • 3. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology. 2009; 136(1): 65-80[DOI][PubMed]
  • 4. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003; 361(9356): 512-9[DOI][PubMed]
  • 5. O'Hara AM, Shanahan F. Gut microbiota: mining for therapeutic potential. Clin Gastroenterol Hepatol. 2007; 5(3): 274-84[DOI][PubMed]
  • 6. Imani Fooladi AA, Mousavi SF, Seghatoleslami S, Yazdani S, Nourani MR. Toll-like receptors: role of inflammation and commensal bacteria. Inflamm Allergy Drug Targets. 2011; 10(3): 198-207[PubMed]
  • 7. Imanifooladi AA, Yazdani S, Nourani MR. The role of nuclear factor-kappaB in inflammatory lung disease. Inflamm Allergy Drug Targets. 2010; 9(3): 197-205[PubMed]
  • 8. Zhang G, Ghosh S. Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest. 2001; 107(1): 13-9[DOI][PubMed]
  • 9. Quigley EM. Prebiotics and probiotics; modifying and mining the microbiota. Pharmacol Res. 2010; 61(3): 213-8[DOI][PubMed]
  • 10. Cesaro C, Tiso A, Del Prete A, Cariello R, Tuccillo C, Cotticelli G, et al. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis. 2011; 43(6): 431-8[DOI][PubMed]
  • 11. Riordan SM, Williams R. The intestinal flora and bacterial infection in cirrhosis. J Hepatol. 2006; 45(5): 744-57[DOI][PubMed]
  • 12. Luyer MD, Buurman WA, Hadfoune M, Speelmans G, Knol J, Jacobs JA, et al. Strain-specific effects of probiotics on gut barrier integrity following hemorrhagic shock. Infect Immun. 2005; 73(6): 3686-92[DOI][PubMed]
  • 13. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 2004; 126(2): 520-8[PubMed]
  • 14. Bauer TM, Steinbruckner B, Brinkmann FE, Ditzen AK, Schwacha H, Aponte JJ, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol. 2001; 96(10): 2962-7[DOI][PubMed]
  • 15. Chang CS, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 1998; 28(5): 1187-90[DOI][PubMed]
  • 16. Gunnarsdottir SA, Sadik R, Shev S, Simren M, Sjovall H, Stotzer PO, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol. 2003; 98(6): 1362-70[DOI][PubMed]
  • 17. Madrid AM, Hurtado C, Venegas M, Cumsille F, Defilippi C. Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol. 2001; 96(4): 1251-5[DOI][PubMed]
  • 18. Salzman AL, Menconi MJ, Unno N, Ezzell RM, Casey DM, Gonzalez PK, et al. Nitric oxide dilates tight junctions and depletes ATP in cultured Caco-2BBe intestinal epithelial monolayers. Am J Physiol. 1995; 268(2 Pt 1)-73[PubMed]
  • 19. Such J, Guardiola JV, de Juan J, Casellas JA, Pascual S, Aparicio JR, et al. Ultrastructural characteristics of distal duodenum mucosa in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2002; 14(4): 371-6[PubMed]
  • 20. Misra V, Misra SP, Dwivedi M, Gupta SC. Histomorphometric study of portal hypertensive enteropathy. Am J Clin Pathol. 1997; 108(6): 652-7[PubMed]
  • 21. Ramachandran A, Prabhu R, Thomas S, Reddy JB, Pulimood A, Balasubramanian KA. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals. Hepatology. 2002; 35(3): 622-9[DOI][PubMed]
  • 22. Bode C, Bode JC. Effect of alcohol consumption on the gut. Best Pract Res Clin Gastroenterol. 2003; 17(4): 575-92[PubMed]
  • 23. Visapaa JP, Tillonen J, Salaspuro M. Microbes and mucosa in the regulation of intracolonic acetaldehyde concentration during ethanol challenge. Alcohol Alcohol. 2002; 37(4): 322-6[PubMed]
  • 24. Albillos A, de la Hera A, Gonzalez M, Moya JL, Calleja JL, Monserrat J, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology. 2003; 37(1): 208-17[DOI][PubMed]
  • 25. Frances R, Rodriguez E, Munoz C, Zapater P, De la ML, Ndongo M, et al. Intracellular cytokine expression in peritoneal monocyte/macrophages obtained from patients with cirrhosis and presence of bacterial DNA. Eur J Gastroenterol Hepatol. 2005; 17(1): 45-51[PubMed]
  • 26. Frances R, Munoz C, Zapater P, Uceda F, Gascon I, Pascual S, et al. Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut. 2004; 53(6): 860-4[PubMed]
  • 27. Rimola A, Soto R, Bory F, Arroyo V, Piera C, Rodes J. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology. 1984; 4(1): 53-8[PubMed]
  • 28. Levi AC, Borghi F, Petrino R, Bargoni A, Fronticelli CM, Gentilli S. Modifications of the trophism of intestinal mucosa after intestinal and bilio-pancreatic diversion in the rat. Ital J Gastroenterol. 1991; 23(4): 202-7[PubMed]
  • 29. Culligan EP, Hill C, Sleator RD. Probiotics and gastrointestinal disease: successes, problems and future prospects. Gut Pathog. 2009; 1(1): 19[DOI][PubMed]
  • 30. Metchnikoff E. The prolongation of life: Optimistic studies. 1907; : 161-83
  • 31. Lin WH, Hwang CF, Chen LW, Tsen HY. Viable counts, characteristic evaluation for commercial lactic acid bacteria products. Food Microbiol. 2006; 23(1): 74-81[DOI][PubMed]
  • 32. Gupta V, Garg R. Probiotics. Indian J Med Microbiol. 2009; 27(3): 202-9[DOI][PubMed]
  • 33. Parvez S, Malik KA, Ah Kang S, Kim HY. Probiotics and their fermented food products are beneficial for health. J Appl Microbiol. 2006; 100(6): 1171-85[DOI][PubMed]
  • 34. Khani S, Hosseini HM, Taheri M, Nourani MR, Imani Fooladi AA. Probiotics as an alternative strategy for prevention and treatment of human diseases: a review. Inflamm Allergy Drug Targets. 2012; 11(2): 79-89[PubMed]
  • 35. Ndagijimana M, Laghi L, Vitali B, Placucci G, Brigidi P, Guerzoni ME. Effect of a synbiotic food consumption on human gut metabolic profiles evaluated by (1)H Nuclear Magnetic Resonance spectroscopy. Int J Food Microbiol. 2009; 134(1-2): 147-53[DOI][PubMed]
  • 36. Cope K, Risby T, Diehl AM. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology. 2000; 119(5): 1340-7[PubMed]
  • 37. Khosravi S, Alavian SM, Zare A, Daryani NE, Fereshtehnejad SM, Keramati MR, et al. Non-alcoholic fatty liver disease and correlation of serum alanin aminotransferase level with histopathologic findings. Hepat Mon. 2011; 11(6): 452-8[PubMed]
  • 38. Law K, Brunt EM. Nonalcoholic fatty liver disease. Clin Liver Dis. 2010; 14(4): 591-604[DOI][PubMed]
  • 39. Compare D, Coccoli P, Rocco A, Nardone OM, De Maria S, Carteni M, et al. Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2012; 22(6): 471-6[DOI][PubMed]
  • 40. Gramenzi A, Caputo F, Biselli M, Kuria F, Loggi E, Andreone P, et al. Review article: alcoholic liver disease--pathophysiological aspects and risk factors. Aliment Pharmacol Ther. 2006; 24(8): 1151-61[DOI][PubMed]
  • 41. Bode C, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol. 1987; 4(1): 8-14[PubMed]
  • 42. Fukui H, Brauner B, Bode JC, Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol. 1991; 12(2): 162-9[PubMed]
  • 43. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology. 1988; 8(2): 232-6[PubMed]
  • 44. Thurman RG. II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol. 1998; 275(4 Pt 1)-11[PubMed]
  • 45. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000; 343(20): 1467-76[DOI][PubMed]
  • 46. Banan A, Fields JZ, Decker H, Zhang Y, Keshavarzian A. Nitric oxide and its metabolites mediate ethanol-induced microtubule disruption and intestinal barrier dysfunction. J Pharmacol Exp Ther. 2000; 294(3): 997-1008[PubMed]
  • 47. Banan A, Keshavarzian A, Zhang L, Shaikh M, Forsyth CB, Tang Y, et al. NF-kappaB activation as a key mechanism in ethanol-induced disruption of the F-actin cytoskeleton and monolayer barrier integrity in intestinal epithelium. Alcohol. 2007; 41(6): 447-60[DOI][PubMed]
  • 48. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006; 43(2 Suppl 1)-31[DOI][PubMed]
  • 49. Chu CJ, Lee FY, Wang SS, Lu RH, Tsai YT, Lin HC, et al. Hyperdynamic circulation of cirrhotic rats with ascites: role of endotoxin, tumour necrosis factor-alpha and nitric oxide. Clin Sci (Lond). 1997; 93(3): 219-25[PubMed]
  • 50. Guarner C, Soriano G, Tomas A, Bulbena O, Novella MT, Balanzo J, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology. 1993; 18(5): 1139-43[PubMed]
  • 51. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest. 1999; 104(9): 1223-33[DOI][PubMed]
  • 52. Faubion WA, Jr., Loftus EV, Sandborn WJ, Freese DK, Perrault J. Pediatric "PSC-IBD": a descriptive report of associated inflammatory bowel disease among pediatric patients with psc. J Pediatr Gastroenterol Nutr. 2001; 33(3): 296-300[PubMed]
  • 53. Grant AJ, Lalor PF, Hubscher SG, Briskin M, Adams DH. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology. 2001; 33(5): 1065-72[DOI][PubMed]
  • 54. Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr. 2008; 47(1): 61-7[DOI][PubMed]
  • 55. Elfaki DA, Lindor KD. Antibiotics for the treatment of primary sclerosing cholangitis. Am J Ther. 2011; 18(3): 261-5[DOI][PubMed]
  • 56. Blei AT, Cordoba J. Hepatic Encephalopathy. Am J Gastroenterol. 2001; 96(7): 1968-76[DOI][PubMed]
  • 57. Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol. 2001; 34(5): 768-73[PubMed]
  • 58. Solga SF. Probiotics can treat hepatic encephalopathy. Med Hypotheses. 2003; 61(2): 307-13[PubMed]
  • 59. Alavian SM, Gholami B, Masarrat S. Hepatitis C risk factors in Iranian volunteer blood donors: a case-control study. J Gastroenterol Hepatol. 2002; 17(10): 1092-7[PubMed]
  • 60. Sozinov AS. Possible participation of endotoxin of gram-negative bacteria in pathogenesis of liver damage during viral hepatitis. Bull Exp Biol Med. 2002; 133(3): 281-4[PubMed]
  • 61. Sozinov AS. Systemic endotoxemia during chronic viral hepatitis. Bull Exp Biol Med. 2002; 133(2): 153-5[PubMed]
  • 62. Chen C, Li L, Wu Z, Chen H, Fu S. Effects of lactitol on intestinal microflora and plasma endotoxin in patients with chronic viral hepatitis. J Infect. 2007; 54(1): 98-102[DOI][PubMed]
  • 63. El-Nezami HS, Polychronaki NN, Ma J, Zhu H, Ling W, Salminen EK, et al. Probiotic supplementation reduces a biomarker for increased risk of liver cancer in young men from Southern China. Am J Clin Nutr. 2006; 83(5): 1199-203[PubMed]
  • 64. Kumar M, Verma V, Nagpal R, Kumar A, Gautam SK, Behare PV, et al. Effect of probiotic fermented milk and chlorophyllin on gene expressions and genotoxicity during AFB(1)-induced hepatocellular carcinoma. Gene. 2011; 490(1-2): 54-9[DOI][PubMed]
  • 65. Smela ME, Currier SS, Bailey EA, Essigmann JM. The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. Carcinogenesis. 2001; 22(4): 535-45[PubMed]
  • 66. Yeh FS, Yu MC, Mo CC, Luo S, Tong MJ, Henderson BE. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res. 1989; 49(9): 2506-9[PubMed]
  • 67. Kanauchi O, Fujiyama Y, Mitsuyama K, Araki Y, Ishii T, Nakamura T, et al. Increased growth of Bifidobacterium and Eubacterium by germinated barley foodstuff, accompanied by enhanced butyrate production in healthy volunteers. Int J Mol Med. 1999; 3(2): 175-9[PubMed]
  • 68. Johnson-Henry KC, Donato KA, Shen-Tu G, Gordanpour M, Sherman PM. Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function. Infect Immun. 2008; 76(4): 1340-8[DOI][PubMed]
  • 69. Zhao HY, Wang HJ, Lu Z, Xu SZ. Intestinal microflora in patients with liver cirrhosis. Chin J Dig Dis. 2004; 5(2): 64-7[PubMed]
  • 70. O'Sullivan DJ. Genomics can advance the potential for probiotic cultures to improve liver and overall health. Curr Pharm Des. 2008; 14(14): 1376-81[PubMed]
  • 71. Clausen MR, Mortensen PB. Lactulose, disaccharides and colonic flora. Clinical consequences. Drugs. 1997; 53(6): 930-42[PubMed]
  • 72. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009; 49(6): 1877-87[DOI][PubMed]
  • 73. Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P, et al. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr. 2009; 139(5): 905-11[DOI][PubMed]
  • 74. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003; 37(2): 343-50[DOI][PubMed]
  • 75. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005; 39(6): 540-3[PubMed]
  • 76. Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol. 2008; 49(5): 821-30[DOI][PubMed]
  • 77. Solga SF, Buckley G, Clark JM, Horska A, Diehl AM. The effect of a probiotic on hepatic steatosis. J Clin Gastroenterol. 2008; 42(10): 1117-9[DOI][PubMed]
  • 78. Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology. 2009; 49(3): 989-97[DOI][PubMed]
  • 79. Vleggaar FP, Monkelbaan JF, van Erpecum KJ. Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol. 2008; 20(7): 688-92[DOI][PubMed]
  • 80. Shimizu M, Iwasaki H, Mase S, Yachie A. Successful treatment of primary sclerosing cholangitis with a steroid and a probiotic. Case Rep Gastroenterol. 2012; 6(2): 249-53[DOI][PubMed]
  • 81. El-Nezami H, Kankaanpää P, Suomalainen T, Ahokas J, Salminen S. The ability of a mixture of Lactobacillus and Propionibacterium to influence the faecal recovery of aflatoxins in healthy Egyptian volunteers: a pilot clinical study. Biosci Microflora. 2000; 19(4): 41-5
  • 82. Rayes N, Seehofer D, Hansen S, Boucsein K, Muller AR, Serke S, et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation. 2002; 74(1): 123-7[PubMed]
  • 83. Lee HY, Park JH, Seok SH, Baek MW, Kim DJ, Lee KE, et al. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim Biophys Acta. 2006; 1761(7): 736-44[DOI][PubMed]
  • 84. Paik HD, Park JS, Park E. Effects of Bacillus polyfermenticus SCD on lipid and antioxidant metabolisms in rats fed a high-fat and high-cholesterol diet. Biol Pharm Bull. 2005; 28(7): 1270-4[PubMed]
  • 85. Yadav H, Jain S, Sinha PR. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition. 2007; 23(1): 62-8[DOI][PubMed]
  • 86. Wang Y, Xu N, Xi A, Ahmed Z, Zhang B, Bai X. Effects of Lactobacillus plantarum MA2 isolated from Tibet kefir on lipid metabolism and intestinal microflora of rats fed on high-cholesterol diet. Appl Microbiol Biotechnol. 2009; 84(2): 341-7[DOI][PubMed]
  • 87. Nardone G, Compare D, Liguori E, Di Mauro V, Rocco A, Barone M, et al. Protective effects of Lactobacillus paracasei F19 in a rat model of oxidative and metabolic hepatic injury. Am J Physiol Gastrointest Liver Physiol. 2010; 299(3)-76[DOI][PubMed]
  • 88. Loguercio C, De Simone T, Federico A, Terracciano F, Tuccillo C, Di Chicco M, et al. Gut-liver axis: a new point of attack to treat chronic liver damage? Am J Gastroenterol. 2002; 97(8): 2144-6[DOI][PubMed]
  • 89. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011; 15(9): 1090-5[PubMed]
  • 90. Nanji AA, Khettry U, Sadrzadeh SM. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med. 1994; 205(3): 243-7[PubMed]
  • 91. Forsyth CB, Farhadi A, Jakate SM, Tang Y, Shaikh M, Keshavarzian A. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol. 2009; 43(2): 163-72[DOI][PubMed]
  • 92. Mutlu E, Keshavarzian A, Engen P, Forsyth CB, Sikaroodi M, Gillevet P. Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res. 2009; 33(10): 1836-46[DOI][PubMed]
  • 93. Segawa S, Wakita Y, Hirata H, Watari J. Oral administration of heat-killed Lactobacillus brevis SBC8803 ameliorates alcoholic liver disease in ethanol-containing diet-fed C57BL/6N mice. Int J Food Microbiol. 2008; 128(2): 371-7[DOI][PubMed]
  • 94. Lata J, Novotny I, Pribramska V, Jurankova J, Fric P, Kroupa R, et al. The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastroenterol Hepatol. 2007; 19(12): 1111-3[DOI][PubMed]
  • 95. Stadlbauer V, Mookerjee RP, Hodges S, Wright GA, Davies NA, Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol. 2008; 48(6): 945-51[DOI][PubMed]
  • 96. Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol. 2008; 42(8): 675-82[DOI][PubMed]
  • 97. Chiva M, Soriano G, Rochat I, Peralta C, Rochat F, Llovet T, et al. Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol. 2002; 37(4): 456-62[PubMed]
  • 98. Bauer TM, Fernandez J, Navasa M, Vila J, Rodes J. Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis. J Hepatol. 2002; 36(4): 501-6[PubMed]
  • 99. Adawi D, Ahrne S, Molin G. Effects of different probiotic strains of Lactobacillus and Bifidobacterium on bacterial translocation and liver injury in an acute liver injury model. Int J Food Microbiol. 2001; 70(3): 213-20[PubMed]
  • 100. Pereg D, Kotliroff A, Gadoth N, Hadary R, Lishner M, Kitay-Cohen Y. Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition. 2011; 27(2): 177-81[DOI][PubMed]
  • 101. Pawar R, Pardeshi M, Ghongane B. Study of Effects of Probiotic Lactobacilli in Preventing Major Complications in Patients of Liver Cirrhosis. Intl J Biomed Pharma Sci. 2012; 3(1): 206-11
  • 102. Tandon P, Moncrief K, Madsen K, Arrieta MC, Owen RJ, Bain VG, et al. Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study. Liver Int. 2009; 29(7): 1110-5[DOI][PubMed]
  • 103. Liu JE, Zhang Y, Zhang J, Dong PL, Chen M, Duan ZP. Probiotic yogurt effects on intestinal flora of patients with chronic liver disease. Nurs Res. 2010; 59(6): 426-32[DOI][PubMed]
  • 104. Lata J, Jurankova J, Pribramska V, Fric P, Senkyrik M, Dite P, et al. [Effect of administration of Escherichia coli Nissle (Mutaflor) on intestinal colonisation, endo-toxemia, liver function and minimal hepatic encephalopathy in patients with liver cirrhosis]. Vnitr Lek. 2006; 52(3): 215-9[PubMed]
  • 105. Loguercio C, Abbiati R, Rinaldi M, Romano A, Del Vecchio Blanco C, Coltorti M. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol. 1995; 23(1): 39-46[PubMed]
  • 106. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology. 2004; 39(5): 1441-9[DOI][PubMed]
  • 107. Malaguarnera M, Greco F, Barone G, Gargante MP, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci. 2007; 52(11): 3259-65[DOI][PubMed]
  • 108. Mittal V, Sharma P, Sharma B, Sarin S. Treatment of minimal hepatic encephalopathy: A randomised controlled trial comparing lactulose, probiotics and l-ornithine l-aspartate with placebo. Hepatology. 2009; 50(4 Suppl): 41A
  • 109. Bajaj JS, Saeian K, Christensen KM, Hafeezullah M, Varma RR, Franco J, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol. 2008; 103(7): 1707-15[DOI][PubMed]
  • 110. Rayes N, Seehofer D, Theruvath T, Schiller RA, Langrehr JM, Jonas S, et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation--a randomized, double-blind trial. Am J Transplant. 2005; 5(1): 125-30[DOI][PubMed]
  • 111. Eguchi S, Takatsuki M, Hidaka M, Soyama A, Ichikawa T, Kanematsu T. Perioperative synbiotic treatment to prevent infectious complications in patients after elective living donor liver transplantation: a prospective randomized study. Am J Surg. 2011; 201(4): 498-502[DOI][PubMed]
  • 112. Pawlowska J, Klewicka E, Czubkowski P, Motyl I, Jankowska I, Libudzisz Z, et al. Effect of Lactobacillus casei DN-114001 application on the activity of fecal enzymes in children after liver transplantation. Transplant Proc. 2007; 39(10): 3219-21[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments